Precision For Medicine
2,056 employees on LinkedIn · 3 known investors
Precision for Medicine is a contract research organization that provides clinical trial management and regulatory support for drug development programs, including oncology, hematology, cell and gene therapy, CAR-T, and radiopharmaceutical trials. It serves pharmaceutical and biotech sponsors running multinational Phase I–IV studies.
Also known as Precision for Medicine · Precision For Medicine, Inc.
Investors · 3
Company profile
researched Aug 2026Precision for Medicine is a global clinical research organization focused on precision-medicine and biomarker-driven drug development. It combines CRO trial execution with laboratory sciences, positioning itself as an integrated provider covering early- through late-phase development, including protocol execution, patient recruitment, global regulatory requirements, manufacturing support and commercial readiness. The company describes itself as the first global precision medicine clinical research organization and reports that over 75% of its trials are in oncology and over 50% in early phase development.
Service lines include Global CRO Services; Global Laboratory Services spanning translational and biomarker sciences plus clinical logistics such as kit development and sample management; Biospecimens; Diagnostics and companion diagnostics; Data Intelligence; and Commercialization. The biospecimens business operates biorepositories containing over 4 million specimens (with more than 11 million tissue, cellular and biofluid specimens cited across the business), IRB-approved and clinically annotated inventory, a network of roughly 150 clinical collection sites, prospective collections across 90 medical conditions, pathology capabilities in the US and Europe (IHC, multiplex immunofluorescence, digital pathology) and a library of over 13,000 NGS-characterized oncology biospecimens across more than 20 indications, including H&E images used as AI training sets.
Therapeutic focus areas are oncology and immuno-oncology, rare diseases, autoimmune disease, cell therapy and gene therapy. The company operates within Precision Medicine Group, whose clinical research arm is Precision for Medicine and whose commercialization arm is Precision AQ.
Founding story
Precision Medicine Group was founded in 2012 by co-founders including Mark P. Clein and Ethan D. Leder to transform the process of bringing new drugs to market by integrating science, technology, data and human expertise, growing through organic investment and acquisitions. The company has said its unusual name reflects a conviction formed at founding that precision medicine and the novel approaches needed to develop such therapeutics represented a step change in medicine.
Business model
Precision for Medicine is a fee-for-service contract research and laboratory services provider to biopharmaceutical sponsors. It sells clinical trial execution (CRO services), central and specialty laboratory and translational science services, biospecimen products and custom collections, diagnostics and companion diagnostic development, and data intelligence products. Biospecimens are sold both as ready-to-ship catalog inventory and as custom collection programs covering recruitment, kitting, collection and logistics. The company operates as part of Precision Medicine Group, which also houses a commercialization business, Precision AQ.
Revenue is generated from services and products sold to drug developers: clinical trial management and CRO services, central and specialty laboratory testing, translational and biomarker science, clinical logistics and sample management, sales of catalog and custom-collected human biospecimens, diagnostics and companion diagnostic development, data intelligence software and analytics, and commercialization support. Third-party estimates place annual revenue between $500 million and $1 billion as of July 2026.
Traction
Reported scale includes approximately 3,500 employees, around 35 offices, roughly 2,500 clinical trial and laboratory projects, five specialty labs in North America and Europe, more than 11 million biospecimens available, biorepositories of over 4 million specimens, 150 global clinical collection sites and prospective collections across 90 medical conditions. External estimates put annual revenue at $500M-$1B as of July 2026 and headcount at about 2,000 professionals. The company won the 2025 Fierce Biotech CRO Award for Innovative Solutions in Drug Development.
Latest developments
In 2025-2026 the company expanded its Asia-Pacific footprint with new offices in Singapore (February 2026) and Japan (March 2026) and added senior leaders: Nicholas Richardson (September 2025) and Paz Vellanki (May 2026), both from the FDA, in clinical development; Chris Clendening (July 2026) as General Manager, Labs Translational Sciences; and Amanda Owens (August 2026) as General Manager, Biospecimen Solutions. It won the 2025 Fierce Biotech CRO Award for Innovative Solutions in Drug Development for rescuing a high-risk hematology-oncology trial, and parent Precision Medicine Group launched Institute@Precision in November 2025.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as a specialized, mid-sized global CRO with strength in oncology, rare disease and biomarker-driven research, explicitly contrasting itself with the "big five" CROs. Third-party data lists comparable companies including IQVIA, Parexel, PPD, Syneos Health, Covance, Premier Research, Medidata Solutions and Veeva Systems, and estimates annual revenue in the $500M-$1B range as of July 2026. The company reports about 2,500 clinical trial and lab projects and states that biotech clients it works with have raised roughly $30 billion in investment over the last five years.
The company positions itself as a "right-sized" alternative to the largest CROs, stating that staff are assigned to no more than two or three trials at a time to provide greater attention per program. It emphasizes integration of laboratory and trial execution under one organization, translational and biomarker science depth, an in-house biospecimen inventory and collection network, and a unified, AI-enabled data ecosystem including a conversational AI virtual assistant for data queries. Senior clinical development staff include multiple former FDA oncology and hematology regulators.
Technology
Capabilities include translational and biomarker science, advanced genomic and NGS characterization, liquid biopsy, flow cytometry immune-cell profiling, PBMC isolation and other specimen processing, immunohistochemistry across major staining platforms, multiplex immunofluorescence and digital pathology with in-house pathologists, plus IVD assay development support. Data intelligence offerings provide a unified, AI-enabled data ecosystem covering sample management, biomarker data analysis and biostatistics, including a conversational AI virtual assistant. Third-party profiling lists technologies in use such as SAS/STAT, Microsoft Azure, Amazon ALB, git, LinkedIn Insight Tag, AdRoll and TrackJS.
Go-to-market
The company sells directly to pharmaceutical and biotech sponsors through a commercial organization led by a Chief Commercial Officer focused on strategic account management and expanding key customer segments, supported by request-a-quote and contact-sales flows on its website, a biospecimens product catalog for direct ordering, published case studies, brochures and insight content, industry awards, conference and forum participation, and senior scientific and ex-regulatory hires used to demonstrate domain credibility.
Pharmaceutical and biotechnology sponsors developing complex therapies, from small biotechs to top-20 pharma, as well as research hospitals and diagnostics developers, particularly those working in oncology and immuno-oncology, rare disease, autoimmune disease, cell therapy and gene therapy, and those requiring biomarker-driven or companion-diagnostic-enabled trials.
Geography
Global operations spanning North America, Europe and Asia, described as approximately 35 offices and a presence across six continents. Five specialty laboratories are located in North America and Europe, with dedicated tissue analysis capabilities in both the US and Europe, and a global network of about 150 clinical collection sites. The company is headquartered in Bethesda, Maryland, based on its press release datelines, and has expanded in Asia-Pacific with offices in Singapore (2026) and Japan (2026), plus dedicated leadership for Asia Pacific and India.
History
The company traces its origin to 2012, when Precision Medicine Group was founded to integrate science, technology, data and human expertise in bringing new drugs to market, growing through both organic investment and acquisitions. Precision for Medicine states more than 25 years of experience conducting clinical trials and in early oncology development. Recent history has centered on leadership build-out and geographic expansion: former FDA officials Nicholas Richardson (September 2025), Paz Vellanki (May 2026) joined clinical development, laboratory executive Chris Clendening joined in July 2026 to lead specialty labs, and Amanda Owens joined in August 2026 for biospecimen solutions. Offices opened in Singapore (February 2026) and Japan (March 2026). In November 2025 parent Precision Medicine Group launched Institute@Precision, a collaborative forum for biopharma innovation.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 6
by search overlap
Companies competing with Precision For Medicine for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 9
launches, deals, and filingsAmanda Owens joined Precision for Medicine to expand access to fit-for-purpose biospecimens for advanced research.
Laboratory industry veteran Chris Clendening joined Precision for Medicine to lead its specialty labs, announced from Bethesda, Md.
Former FDA official Paz Vellanki joined Precision for Medicine, forming a trio of former regulatory leaders at the company.
A solution was recognized as the best answer to the health challenge defined by Precision for Medicine at the II Innovation Forum of the RETECH-Madrid Community project.
Precision for Medicine opened a new office in Japan, continuing its Asia-Pacific expansion.
Precision for Medicine opened a new office in Singapore, expanding its Asia-Pacific presence.
Parent company Precision Medicine Group launched Institute@Precision, a collaborative forum for biopharma innovation.
Nicholas Richardson left his role as deputy director at the US FDA overseeing hematologic malignancies to join Precision for Medicine as vice president, clinical development.
Awarded for the rescue of a high-risk hematology-oncology trial involving an operational and data gap analysis, centralized patient-level data monitoring and custom tracking systems.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Precision For Medicineprecisionformedicine.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Precision For Medicine do?
- Global precision-medicine CRO combining oncology and rare-disease trial execution with laboratory, biospecimen and data services.
- Who are Precision For Medicine's investors?
- Precision For Medicine's investors include J.H. Whitney, Oak HC/FT, TPG.